All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The Psoriasis and Psoriatic Arthritis Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Psoriasis and Psoriatic Arthritis Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Psoriasis and Psoriatic Arthritis Hub cannot guarantee the accuracy of translated content. The Psoriasis and Psoriatic Arthritis Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
Disease AreasTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
Add bookmark

BE OPTIMAL and BE COMPLETE: 52-week post-hoc analysis of patients with BSA ≥3% and ≥10%

During the EADV 2023 Congress, Thaçi presented a post-hoc analysis of two phase III trials, BE OPTIMAL and BE COMPLETE, of bimekizumab in patients with PsA.

Nov 28, 2023
Add bookmark

Guest article | Management of psoriasis and psoriatic arthritis in patients with comorbidities: A focus on liver disease

The Psoriasis and Psoriatic Arthritis Hub is pleased to present a guest article from Lija James, University of Oxford, Oxford,...

Nov 17, 2023
Add bookmark

Sonelokimab exhibits favorable data in active psoriatic arthritis: Results from the phase II ARGO trial

Topline results from the phase II ARGO trial show that primary and secondary endpoints in efficacy and safety were met in patients with active...

Nov 6, 2023
Add bookmark

Visual abstract | Early guselkumab intervention in psoriasis leads to 'clinical super response': Week 28 results from the phase IIb GUIDE study

The Psoriasis and Psoriatic Arthritis Hub is pleased to present a visual abstract summarizing Week 28...

Nov 6, 2023
Paolo Gisondi

"The Hub is an innovative and valuable tool for healthcare professionals, providing valuable, up-to-date information on the most exciting advances in these areas through expert opinions and case studies - Paolo Gisondi"

Paolo Gisondi

"The Hub is an innovative and valuable tool for healthcare professionals, providing valuable, up-to-date information on the most exciting advances in these areas through expert opinions and case studies - Paolo Gisondi"

Featured Expert Opinion

Add bookmark

Editorial theme | How to select treatments based on patient ​and disease characteristics? 

Laura Coates discusses the complications of selecting the correct treatment when there...

Psoriasis

view more

Psoriatic arthritis

view more

Most Read

EADV 2022

view more

Most Viewed